18. Eder S, Dubischar-Kastner K, Firbas C, et al. Long term immunity following a booster dose <strong>of</strong> the inactivated Japanese encephalitis vaccine IXIARO ® , IC51. Vaccine 2011;29:2607-12. 19. Kaltenböck A, Dubischar-Kastner K, Schuller E, et al. Immunogenicity <strong>and</strong> safety <strong>of</strong> IXIARO ® (IC51) in a Phase II study in healthy Indian children between 1 <strong>and</strong> 3 years <strong>of</strong> age. Vaccine 2010;28:834-9. 20. Dubischar-Kastner K, Kadlecek V, Sablan B, et al. Safety <strong>and</strong> immunogenicity <strong>of</strong> the inactivated Japanese encephalitis vaccine IXIARO ® , IC51, in Filipino children aged 2 months to
6. Brotherton J, Wang H, Schaffer A, et al. Vaccine preventable diseases <strong>and</strong> vaccination coverage in Australia, 2003 to 2005. Communicable Diseases Intelligence 2007;31 Suppl:viii-S152. 7. Chiu C, Dey A, Wang H, et al. Vaccine preventable diseases in Australia, 2005 to 2007. Communicable Diseases Intelligence 2010;34 Suppl:ix-S167. 8. Martin N, Foxwell AR. Measles status in Australia, <strong>and</strong> outbreaks in the first quarter <strong>of</strong> 2009. [erratum appears in Commun Dis Intell. 2010 Jun;34(2):152]. Communicable Diseases Intelligence 2009;33:225-31. 9. Heath T, Burgess M, McIntyre P, Catton M. The national measles surveillance strategy. Communicable Diseases Intelligence 1999;23:41-50. 10. Cottrell S, Roberts RJ. Measles outbreak in Europe [editorial]. BMJ 2011;342:d3724. 11. Hull BP, Mahajan D, Dey A, Menzies RI, McIntyre PB. Immunisation coverage annual report, 2008. Communicable Diseases Intelligence 2010;34:241-58. 12. Commonwealth <strong>Department</strong> <strong>of</strong> <strong>Health</strong> <strong>and</strong> Aged Care. Let‘s work together to beat measles. A report on Australia‘s Measles Control Campaign. Canberra: Commonwealth <strong>Department</strong> <strong>of</strong> <strong>Health</strong> <strong>and</strong> Aged Care, 2000. 13. Turnbull FM, Burgess MA, McIntyre PB, et al. The Australian Measles Control Campaign, 1998. Bulletin <strong>of</strong> the World <strong>Health</strong> Organization 2001;79:882-8. 14. Gidding HF, Gilbert GL. Measles immunity in young Australian adults. Communicable Diseases Intelligence 2001;25:133-6. 15. Lambert SB, Morgan ML, Riddell MA, et al. Measles outbreak in young adults in Victoria, 1999. Medical Journal <strong>of</strong> Australia 2000;173:467-71. 16. NNDSS Annual Report Writing Group. Australia‘s notifiable disease status, 2009: annual report <strong>of</strong> the National Notifiable Diseases Surveillance System. Communicable Diseases Intelligence 2011;35:61-131. 17. McIntyre P, Gidding H, Gilmour R, et al. Vaccine preventable diseases <strong>and</strong> vaccination coverage in Australia, 1999 to 2000. Communicable Diseases Intelligence 2002;26 Suppl:1-111. 18. Huppatz C, Kelly PM, Levi C, et al. Encephalitis in Australia, 1979–2006: trends <strong>and</strong> aetiologies. Communicable Diseases Intelligence 2009;33:192-7. 19. World <strong>Health</strong> Organization (WHO). WHO guidelines for epidemic preparedness <strong>and</strong> response to measles outbreaks. WHO/CDS/CSR/ISR/99.1. Geneva: WHO, 1999. Available at: http://whqlibdoc.who.int/hq/1999/WHO_CDS_CSR_ISR_99.1.pdf (accessed July 2011). 20. Centers for Disease Control <strong>and</strong> Prevention (CDC). Global Measles <strong>and</strong> Rubella Laboratory Network, January 2004–June 2005. MMWR Morbidity <strong>and</strong> Mortality Weekly Report 2005;54:1100-4. 21. Centers for Disease Control <strong>and</strong> Prevention (CDC). Global measles mortality, 2000–2008. MMWR Morbidity <strong>and</strong> Mortality Weekly Report 2009;58:1321-6. 22. Centers for Disease Control <strong>and</strong> Prevention (CDC). Progress toward the 2012 measles elimination goal – Western Pacific Region, 1990–2008. MMWR Morbidity <strong>and</strong> Mortality Weekly Report 2009;58:669-73. 23. Kelly H, Riddell M, Heywood A, Lambert S. WHO criteria for measles elimination: a critique with <strong>reference</strong> to criteria for polio elimination. Eurosurveillance 2009;14(50):pii=19445. 24. Markowitz LE, Preblud SR, Fine PE, Orenstein WA. Duration <strong>of</strong> live measles vaccine-induced immunity. Pediatric Infectious Disease Journal 1990;9:101-10. 25. Centers for Disease Control <strong>and</strong> Prevention (CDC), Watson JC, Hadler SC, et al. Measles, mumps, <strong>and</strong> rubella – vaccine use <strong>and</strong> strategies for elimination <strong>of</strong> measles, rubella, <strong>and</strong> congenital rubella syndrome <strong>and</strong> control <strong>of</strong> mumps: recommendations <strong>of</strong> the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations <strong>and</strong> Reports 1998;47(RR-8):1-57. 26. Demicheli V, Rivetti A, Debalini MG, Di Pietrantonj C. Vaccines for measles, mumps <strong>and</strong> rubella in children. Cochrane Database <strong>of</strong> Systematic Reviews 2012;(2):CD004407. doi:10.1002/14651858.CD004407.pub3. 27. Uzicanin A, Zimmerman L. Field effectiveness <strong>of</strong> live attenuated measles-containing vaccines: a review <strong>of</strong> published literature. Journal <strong>of</strong> Infectious Diseases 2011;204 Suppl 1:S133-48. 28. Kuter BJ, H<strong>of</strong>fman Brown ML, Hartzel J, et al. Safety <strong>and</strong> immunogenicity <strong>of</strong> a combination measles, mumps, rubella <strong>and</strong> varicella vaccine (ProQuad ® ). Human Vaccines 2006;2:205-14.
- Page 1 and 2: Part 1 Introduction to The Australi
- Page 3 and 4: 2. Hand Hygiene Australia. Grayson
- Page 5 and 6: 4. Centers for Disease Control and
- Page 7 and 8: 45. DeStefano F, Mullooly JP, Okoro
- Page 9 and 10: 35. Hanna JN, Faoagali JL, Buda PJ,
- Page 11 and 12: 2. Mahajan D, Cook J, McIntyre PB,
- Page 13 and 14: 48. Zelinkova Z, de Haar C, de Ridd
- Page 15 and 16: 93. Cheng FW, Ip M, Chu YY, et al.
- Page 17 and 18: 132. Wilkin T, Lee JY, Lensing SY,
- Page 19 and 20: Part 4 Vaccine-preventable diseases
- Page 21 and 22: http://www.immunise.health.gov.au/i
- Page 23 and 24: 6. Hanna JN, Hills SL, Humphreys JL
- Page 25 and 26: 16. Chiu C, Dey A, Wang H, et al. V
- Page 27 and 28: 57. Watkins SL, Alexander SR, Brewe
- Page 29 and 30: 5. Giuliano AR, Harris R, Sedjo RL,
- Page 31 and 32: 48. Tortolero-Luna G. Epidemiology
- Page 33 and 34: 87. Vesikari T, Van Damme P, Lindbl
- Page 35 and 36: http://www.flupandemic.gov.au/inter
- Page 37 and 38: 57. Ciszewski A. Why young healthy
- Page 39: 4.8 Japanese encephalitis Reference
- Page 43 and 44: 45. Levin MJ, Gershon AA, Weinberg
- Page 45 and 46: 19. de Greeff SC, de Melker HE, Spa
- Page 47 and 48: 53. Centers for Disease Control and
- Page 49 and 50: congenital rubella syndrome and con
- Page 51 and 52: http://www.immunise.health.gov.au/i
- Page 53 and 54: 3. Kadioglu A, Weiser JN, Paton JC,
- Page 55 and 56: 44. O‘Brien KL, Hochman M, Goldbl
- Page 57 and 58: 81. Jackson LA, Benson P, Sneller V
- Page 59 and 60: 5. Parker NR, Barralet JH, Bell AM.
- Page 61 and 62: 7. Srinivasan A, Burton EC, Kuehner
- Page 63 and 64: 50. Briggs DJ, Banzhoff A, Nicolay
- Page 65 and 66: 17. Dey A, Wang H, Menzies R, Macar
- Page 67 and 68: 60. GlaxoSmithKline. A study to exp
- Page 69 and 70: 23. Castillo-Solórzano C, Marsigli
- Page 71 and 72: pregnant women, and surveillance fo
- Page 73 and 74: 8. World Health Organization (WHO)
- Page 75 and 76: 13. Sur D, Ochiai RL, Bhattacharya
- Page 77 and 78: 39. Schuster V, Otto W, Maurer L, e
- Page 79 and 80: 81. Klein NP, Lewis E, Baxter R, et
- Page 81 and 82: 12. Simmons A. Management of shingl
- Page 83 and 84: Part 5 Passive Immunisation 5.1 Pas
- Page 85: 11. Sulfaro F, Fasher B, Burgess MA
Change language